CDEK
← All drugs Report issue

bisantrene

Small moleculeexperimental

Clinical trial activity

4 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started Sep 1, 2019 (NCT03820908)

Timeline

2010s

  1. Jan 1, 2019

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2022

    Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

C(=N\NC1=NCCN1)\c1c2ccccc2c(/C=N\NC2=NCCN2)c2ccccc12
Mol. weight
398.47 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • bisantrene
  • bisantrene
  • bisantrene dihydrochloride
  • bisantrene dihydrochloride
  • bisantrene dihydrochloride
  • bisantrene hydrochloride

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06815575Phase 1Apr 2, 2025Race Oncology Ltd
NCT05456269Phase 1Jul 31, 2022Astex Pharmaceuticals, Inc., Race Oncology Ltd
NCT04989335Phase 2Aug 2, 2021Race Oncology Ltd, Tel Aviv University
NCT03820908Phase 2Sep 1, 2019Race Oncology Ltd, Tel Aviv University
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Race Oncology LtdFor profit4222019
Tel Aviv UniversityAcademic/Hospital2212019
Astex Pharmaceuticals, Inc.For profit1012022
3 organizations
Page 1 / 1